Professor Sarah Slight Emeritus Professor David Bates Dr Clare Tolley
| The effect of digital antimicrobial stewardship programmes on antimicrobial usage, length of stay, mortality and cost | 2023 |
|
Professor Sarah Slight Emeritus Professor David Bates Neil Watson
| Electronic prescribing systems in hospitals to improve medication safety: A multimethods research programme | 2022 |
|
Dr Clare Tolley Professor Sarah Slight Professor Andy Husband Neil Watson Emeritus Professor David Bates et al. | Improving medication-related clinical decision support | 2018 |
|
Professor Sarah Slight Emeritus Professor David Bates
| Medication-related clinical decision support alert overrides in inpatients | 2018 |
|
Emeritus Professor David Bates
| Lord Walton of Detchant Obituary | 2016 |
|
Emeritus Professor David Bates
| A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy | 2014 |
|
Emeritus Professor David Bates
| A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica) | 2013 |
|
Emeritus Professor David Bates
| Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool | 2013 |
|
Emeritus Professor David Bates
| Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM | 2013 |
|
Emeritus Professor David Bates
| A Risk-Benefit Analysis of Natalizumab Across PML Risk Sub-Groups in Patients with Relapsing-Remitting Multiple Sclerosis | 2012 |
|
Emeritus Professor David Bates
| Economic Evaluation of Natalizumab Versus Fingolimod for the Treatment of Replapsing-Remitting Multiple Sclerosis in Sweden | 2012 |
|
Emeritus Professor David Bates
| Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity | 2012 |
|
Emeritus Professor David Bates
| Long-term outcomes in patients with multiple sclerosis | 2011 |
|
Emeritus Professor David Bates
| Methodology and validation of urinary incontinence in multiple sclerosis screening tool | 2011 |
|
Emeritus Professor David Bates
| Registry data | 2011 |
|
Emeritus Professor David Bates
| Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials | 2011 |
|
Emeritus Professor David Bates
| The value of uniform MRI protocols in the management and treatment of MS in the West | 2010 |
|
Emeritus Professor David Bates
| Invited lecture 6: The future of therapy in multiple sclerosis | 2009 |
|
Emeritus Professor David Bates Professor John Isaacs
| Should neurologists wait and see or see and treat RRMS? | 2009 |
|
Emeritus Professor David Bates
| Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode | 2009 |
|
Emeritus Professor David Bates
| Future therapies in multiple sclerosis | 2008 |
|
Emeritus Professor David Bates
| Future therapies in multiple sclerosis | 2008 |
|
Dr Vanessa Hogan Dr Kathleen White Emeritus Professor David Bates Emeritus Professor Doug Turnbull Dr Philip Nichols et al. | An increase in axonal mitochondrial density may play a role in axonal loss following myelin degeneration in the Plp1 mouse model of demyelination | 2007 |
|
Professor Patrick Chinnery Dr Douglas Crompton Dr Margaret Jackson Emeritus Professor David Bates Professor Sir John Burn et al. | Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation | 2007 |
|
Emeritus Professor David Bates
| Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring | 2007 |
|
Emeritus Professor David Bates
| Can somatosensory evoked potentials and neuron-specific enolase reliably predict outcome in postanoxic coma? Commentary | 2006 |
|
Dr Helen Andrews Dr Kathryn White Emeritus Professor David Bates Emeritus Professor Doug Turnbull Dr Philip Nichols et al. | Increased axonal mitochondrial activity as an adaptation to myelin deficiency in the Shiverer mouse | 2006 |
|
Emeritus Professor David Bates
| Natalizumab in relapsing multiple sclerosis: appropriate patient selection, management guidelines, and a diagnostic algorithm for the differential diagnosis of new neurologic signs or symptoms | 2006 |
|
Dr Helen Andrews Dr Kathleen White Christopher Thomson Emeritus Professor David Bates Emeritus Professor Doug Turnbull et al. | A role for mitochondria in axonal loss in multiple sclerosis: studies in the Shiverer mouse model | 2005 |
|
Dr Philip Nichols Dr Helen Andrews Dr Kathleen White Emeritus Professor David Bates Emeritus Professor Doug Turnbull et al. | A role for mitochondria in chronic axonal loss in multiple sclerosis: Studies at early and late time points in the shiverer mouse model | 2005 |
|
Dr Helen Andrews Dr Kathleen White Emeritus Professor David Bates Emeritus Professor Doug Turnbull Dr Philip Nichols et al. | A role for mitochondria in chronic axonal loss in multiple sclerosis: studies at early and late time points in the shiverer mouse model | 2005 |
|
Emeritus Professor David Bates
| Disease management in multiple sclerosis | 2005 |
|
Emeritus Professor David Bates
| Disease management in multiple sclerosis | 2005 |
|
Dr Helen Andrews Dr Kathleen White Emeritus Professor David Bates Emeritus Professor Doug Turnbull Dr Philip Nichols et al. | Mitochondria and axonal loss in multiple sclerosis: the missing link? | 2005 |
|
Dr Helen Andrews Dr Kathleen White Christopher Thomson Emeritus Professor David Bates Emeritus Professor Doug Turnbull et al. | Mitochondria and axonal loss in multiple sclerosis: the shiverer mouse as a model of secondary progressive MS | 2005 |
|
Dr Helen Andrews Dr Philip Nichols Emeritus Professor David Bates Emeritus Professor Doug Turnbull
| Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis | 2005 |
|
Dr Douglas Crompton Professor Patrick Chinnery Emeritus Professor David Bates Dr Timothy Walls Dr Margaret Jackson et al. | Spectrum of movement disorders in neuroferritinopathy | 2005 |
|
Dr Daniel Birchall Emeritus Professor David Bates Emerita Professor Katherine Bushby Professor Patrick Chinnery
| Subclinical semitendinosus and obturator externus involvement defines an autosomal dominant myopathy with early respiratory failure | 2005 |
|
Emeritus Professor David Bates
| The vegetative state and the Royal College of Physicians guidance | 2005 |
|
Professor Mark Baker Professor John Isaacs Dr Peter Fawcett Emeritus Professor David Bates
| Treatment of stiff person syndrome with rituximab | 2005 |
|
Dr Martin Barron Philip Griffiths Emeritus Professor Doug Turnbull Emeritus Professor David Bates Dr Philip Nichols et al. | The distributions of mitochondria and sodium channels reflect the specific energy requirements and conduction properties of the human optic nerve head | 2004 |
|
Emeritus Professor David Bates
| The way forward to treatment optimisation in multiple sclerosis: Introduction | 2004 |
|
Dr Martin Barron Emeritus Professor Doug Turnbull Emeritus Professor David Bates Dr Philip Nichols
| [abstract] Neuronal loss in Multiple Sclerosis: Role of Mitochondria in the Axonal response to Demyelination | 2003 |
|
Dr Hazel Powell Dr Sally Lynch Emeritus Professor David Bates Dr Ann Curtis
| A deletion within the frataxin gene, combined with a GAA expansion mutation causes atypical Friedreich ataxia | 2003 |
|
Emeritus Professor David Bates
| The effectiveness of Natalizumab on MRI outcome measures in patients with relapsing multiple sclerosis | 2003 |
|
Emeritus Professor David Bates
| The vegetative state: guidance on diagnosis and management - A report of a working party of the Royal College of Physicians | 2003 |
|
Professor Patrick Chinnery Andrew Curtis Constanze Fey Dr Margaret Jackson Emeritus Professor David Bates et al. | Neuroferritinopathy | 2002 |
|
Dr Douglas Crompton Professor Patrick Chinnery Constanze Fey Andrew Curtis Dr Christopher Morris et al. | Neuroferritinopathy: A window on the role of iron in neurodegeneration | 2002 |
|
Professor Patrick Chinnery Dr Timothy Walls Professor Michael Hanna Emeritus Professor David Bates Dr Peter Fawcett et al. | Normokalemic periodic paralysis revisited: Does it exist? | 2002 |
|
Andrew Curtis Constanze Fey Dr Christopher Morris Professor Laurence Bindoff Professor Patrick Chinnery et al. | Mutation in ferritin light chain causes dominant adult onset neurodegeneration | 2001 |
|
Andrew Curtis Constanze Fey Dr Christopher Morris Professor Laurence Bindoff Professor Patrick Chinnery et al. | Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease | 2001 |
|
Emeritus Professor David Bates
| PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS | 2001 |
|
Emeritus Professor David Bates
| Randomized controlled trial of interferon-beta-1a in secondary progressive MS - Clinical results | 2001 |
|
Emeritus Professor David Bates
| The prognosis of medical coma | 2001 |
|
Professor Sir John Burn Andrew Curtis Dr Matthew Jackson Constanze Fey Emeritus Professor David Bates et al. | A novel autosomal dominant basal ganglia degeneration with cavitation on 19q can mimic Parkinson's disease and Huntington's disease | 2000 |
|
Dr David Parkin Emeritus Professor David Bates
| Costs and quality of life in multiple sclerosis: a cross-sectional observational study in the UK | 2000 |
|
Emeritus Professor David Bates Professor Simon Thomas
| Multiple sclerosis: care needs for 2000 and beyond | 2000 |
|
Dr David Parkin Dr Ann Jacoby Paul McNamee Paul Miller Professor Simon Thomas et al. | Treatment of multiple sclerosis with interferon β: An appraisal of cost-effectiveness and quality of life | 2000 |
|
Professor David Burn Emeritus Professor David Bates
| Quantitative analysis of MRI signal intensity in new variant Creutzfeldt-Jakob disease | 1999 |
|
Professor Robert Taylor Professor Patrick Chinnery Emeritus Professor David Bates Dr Margaret Jackson Dr Margaret Johnson et al. | A novel mitochondrial DNA point mutation in the tRNA(Ile) gene: Studies in a patient presenting with chronic progressive external ophthalmoplegia and multiple sclerosis | 1998 |
|